Spotlight on ViroMed’s CAD Gene-Therapeutic VM202 in the 1st page of the Prestigious Medical Journal Radiology
- Effectiveness against myocardial infarction verified using MRI by researchers at the University of California, San Francisco’s School of Medicine. - Expected to enable the company to find a global partner to further develop and commercialize VM202 for the worldwide market.
SEOUL, KOREA, Sep. 10 – ViroMed Co., Ltd. (KOSDAQ: 084990) today announced that an article on the therapeutic effect of ViroMed’s CAD gene-therapeutic VM202 and the supporting MRI evidence will be published in the October issue of the prestigious medical journal Radiology (posted online, Sep. 16). VM202’s clinical promise due to its multiple potential benefits is also acknowledged in a separate column titled Science to Practice on the 1st page of the same journal, from the work being conducted at the University of California, San Francisco's School of Medicine (UCSF) by Dr. Maythem Saeed and his team of researchers.
VM202 is a pioneering bio-therapeutic developed wholly by Korean researchers and is currently undergoing clinical trials in the US, Korea, and China.
The work was started in 2006 at the request of UCSF researchers who were able to see its potential benefits. The researchers used a new type of MRI that can diagnose coronary artery disease more accurately, and were able to effectively measure the excellent efficacy of VM202 using a swine model.
The corresponding author of the article, Dr. Saeed, is a world leader in the field of cardiovascular radiology. Recently, another article by the same author on the evidence of the therapeutic effectiveness of VM202 was published in the American Journal of Physiology.
"Confirming the revival of heart tissue damaged by myocardial infarction through the use of MRI makes this work very meaningful," said Prof. Tae-Hwan Lim, MD, PhD, of Asan Medical Center’s Department of Radiology and the head of the Asian Society of Cardiovascular Imaging(ASCI). "The therapeutic used in this work (VM202) has already received clinical trial approvals from agencies such as the US FDA and Korea Food and Drug Administration and is currently undergoing clinical trials in the US, Korea, and China. When taking all of these things into consideration, the expectations for the development of a new medicine for myocardial infarction are very high."
"This article provides even more evidence for the efficacy of VM202," said Sunyoung Kim, the CEO of ViroMed. "We will continue to research various methods to improve the therapeutic effectiveness of VM202 through additional collaborations with UCSF. This work is expected to enable our company to find a global partner to further develop and commercialize VM202 for the worldwide market."
VM202 is currently undergoing clinical trials for coronary artery disease (CAD) in Korea and peripheral artery disease (PAD) in the US and China. This article is expected to significantly raise the awareness of the clinical trial for VM202 for CAD in collaboration with Cordis Corp., a Johnson and Johnson company, planned for the second half of this year in the US.